Cme Group INC Form 4 insider transactions

Robert J. Tierney Jr., a Director at CME Group Inc., received a grant of fully vested Class A Common Stock as part of the company's annual equity compensation program.

Martin J. Gepsman, a Director at CME Group Inc., received a grant of 645 fully vested shares of Class A Common Stock as part of the company's annual equity compensation program.

William R. Shepard, a Director at CME Group Inc., reported transactions involving the acquisition of common stock, including grants and dividend reinvestments.

Rahael Seifu, a Director at CME Group Inc., was granted fully vested Class A Common Stock as part of the company's annual equity compensation program.

Dennis Suskind, a Director at CME Group Inc., received a grant of fully vested Class A Common Stock as part of the company's annual equity compensation program.

Howard J. Siegel, a Director at CME Group Inc., reported transactions involving the acquisition of Class A Common Stock.

Patrick J. Mulchrone, a Director at CME Group Inc., received a grant of fully vested Class A Common Stock as part of the company's annual equity compensation program.

Patrick W. Maloney, a Director at CME Group Inc., received a grant of fully vested Class A Common Stock as part of the company's annual equity compensation program.

Deborah J. Lucas, a Director at CME Group Inc., received a grant of fully vested Class A Common Stock as part of the company's annual equity compensation program.

Phyllis M. Lockett, a Director at CME Group Inc., was granted fully vested Class A Common Stock as part of the company's annual equity compensation program.

CME Group Director Daniel G. Kaye was granted fully vested Class A Common Stock as part of the company's annual equity compensation program.

William W. Hobert, a Director at CME Group Inc., has reported several transactions involving Class A Common Stock, including distributions, grants, and elected share issuances.

Harold Eugene Ford Jr. reports transactions involving CME Group Inc. Class A Common Stock, including grants and shares issued in lieu of director fees.

Bryan T. Durkin, a Director at CME Group Inc., received a grant of fully vested Class A Common Stock as part of the company's annual equity compensation program.

Elizabeth A. Cook, a Director at CME Group Inc., received a grant of fully vested Class A Common Stock as part of the annual compensation program.

CME Group Director Charles P. Carey acquired shares through the company's annual equity compensation program and in lieu of cash retainer.

Timothy S. Bitsberger, a Director at CME Group Inc., received a grant of fully vested Class A Common Stock as part of the company's annual equity compensation program.

Hilda Harris Piell, Sr. MD & Chief HR Officer at CME Group Inc., reported a transaction involving 5,753 shares of Common Stock Class A.

CME Group Chairman and CEO Terrence A. Duffy reported the sale of common stock valued at over $10 million.

CME Group director William R. Shepard acquired 1,469.84 Class A shares via dividend reinvestment at $297.38 on March 26, 2026.

CME Group's Senior MD General Counsel, Jonathan L. Marcus, filed an amended Form 4 to correct the reported sale price of 3,291 shares of common stock.

CME Group's Senior MD and General Counsel, Jonathan L. Marcus, sold 3,291 shares of Class A Common Stock for $333.37 per share under a pre-arranged 10b5-1 plan.

CME Group's Sr MD Global Head Equity & FX, Timothy Francis McCourt, reported the vesting of performance shares and subsequent tax-related dispositions.

CME Group's Senior Managing Director and General Counsel, Jonathan L. Marcus, reported the vesting of performance shares and subsequent share dispositions for tax obligations.

CME Group's Senior Managing Director and Chief HR Officer, Hilda Harris Piell, received 7,076 shares from a performance award and surrendered 3,039 shares for tax withholding.

CME Group's COO, Suzanne Sprague, reported the vesting of 5,504 performance shares and subsequent tax-related share disposals on March 15, 2026.

CME Group Chairman and CEO Terrence A. Duffy acquired 62,902 shares through performance share vesting and subsequently disposed of 27,866 shares for tax withholding obligations.

CME Group's Chief Transformation Officer, Ken Vroman, reported the vesting of performance shares and subsequent sale for tax obligations.

CME Group's Sr MD Chief Commercial Officer, Julie Winkler, received 8,256 shares from performance share vesting, while surrendering 3,658 shares for tax obligations.

CME Group Senior Managing Director Derek Sammann received performance shares and sold a portion for tax obligations.